Medincell Publishes its Consolidated Annual Financial Results

Medincell reported FY2024-25 revenues of €25.4 million, a 2.8x increase year-over-year, driven by strong UZEDY sales, and total income of €27.7 million. While operating expenses rose 17% to €38.5 million, the operating loss improved 48% to €(10.8) million, and net loss improved 26% to €(18.4) million. The company anticipates operational profitability by FY2027, supported by a strengthened balance sheet with €71.9 million in cash and investments, and expects further revenue acceleration with the potential 2026 approval of its olanzapine LAI; a strategic co-development and licensing agreement was signed with AbbVie in April 2024 for up to $1.9 billion in milestone and commercialization payments.

Analysis

Medincell's fiscal year 2024-25 results demonstrate significant operational progress, highlighted by a 2.8-fold increase in revenues to €25.4 million, primarily fueled by a 3.8x surge in UZEDY royalties to €6.5 million and substantial partnership revenues, including €9.5 million from the AbbVie collaboration. This revenue growth, coupled with a controlled 17% rise in operating expenses to €38.5 million, led to a notable 48% year-over-year improvement in the operating result, narrowing the loss to €(10.8) million, and a 26% improvement in the net result to €(18.4) million. The company's financial position has markedly strengthened, evidenced by €71.9 million in cash, cash equivalents, and low-risk financial investments, and a shift to a net cash position of €7.3 million from a net financial debt of €42.3 million the previous year, significantly bolstered by a €42.9 million fundraising and a $35 million upfront payment from AbbVie. Management anticipates achieving operational profitability by fiscal year 2027, supported by the ongoing UZEDY momentum and the expected 2026 approval and launch of its olanzapine LAI, which has received positive Phase 3 data and patent protection until 2044. While the mdc-CWM Phase 3 study did not meet its primary endpoint, a subgroup analysis showed promise for future development, and other pipeline programs, including those with the Gates Foundation and AbbVie, are advancing. The increased net financial loss to €(7.4) million was primarily driven by a non-cash fair value adjustment of warrants linked to the company's strong stock performance.

Key Decisions for Investors

• Investors should acknowledge Medincell's significant revenue ramp-up, improving loss profile, and strengthened balance sheet as indicators of positive operational execution and a clearer path toward its stated goal of profitability by FY2027.
• Key catalysts to monitor include the FDA review and potential approval of olanzapine LAI in 2026, progress on the six programs under the AbbVie collaboration, and continued UZEDY sales growth, which are pivotal for future value accretion.
• Given the successful capital raise and positive net cash position, investors might consider the company's enhanced financial flexibility to fund its ambitious R&D pipeline and strategic growth initiatives, while also noting the ongoing audit of the consolidated financial statements.